Literature DB >> 25033999

The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report.

Joseph Kattan1, Hampig Raphael Kourie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25033999     DOI： 10.1007/s10637-014-0133-2

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

Review 1.  Breast cancer in men.

Authors:  Sharon H Giordano; Aman U Buzdar; Gabriel N Hortobagyi
Journal:  Ann Intern Med       Date:  2002-10-15       Impact factor: 25.391

2.  Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Authors:  Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

3.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Authors:  Thomas Bachelot; Céline Bourgier; Claire Cropet; Isabelle Ray-Coquard; Jean-Marc Ferrero; Gilles Freyer; Sophie Abadie-Lacourtoisie; Jean-Christophe Eymard; Marc Debled; Dominique Spaëth; Eric Legouffe; Djelila Allouache; Claude El Kouri; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

4.  Male breast cancer in the veterans affairs population: a comparative analysis.

Authors:  Zeina A Nahleh; Roopa Srikantiah; Malek Safa; Abdul-Rahman Jazieh; Albert Muhleman; Rami Komrokji
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

5.  Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors:  Denise A Yardley; Shinzaburo Noguchi; Kathleen I Pritchard; Howard A Burris; José Baselga; Michael Gnant; Gabriel N Hortobagyi; Mario Campone; Barbara Pistilli; Martine Piccart; Bohuslav Melichar; Katarina Petrakova; Francis P Arena; Frans Erdkamp; Wael A Harb; Wentao Feng; Ayelet Cahana; Tetiana Taran; David Lebwohl; Hope S Rugo
Journal:  Adv Ther       Date:  2013-10-25       Impact factor: 3.845
  5 in total
  2 in total

Review 1.  Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment.

Authors:  Guoliang Zheng; Jose Pablo Leone
Journal:  J Oncol       Date:  2022-05-24       Impact factor: 4.501

2.  Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report.

Authors:  Z Ballatore; M Pistelli; N Battelli; A Pagliacci; M De Lisa; R Berardi; S Cascinu
Journal:  BMC Res Notes       Date:  2016-11-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.